Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin versus empagliflozin in type 2 diabetes mellitus with mild to moderate hypertension
2017-002309-36Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sotagliflozin QD with Empagliflozin QD (2 arms). Primary endpoint: Pharmacodynamic parameters in feces. Started Nov 2017; status: completed.
02
Drugs
sotagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-002309-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002309-36.